Allergic contact dermatitis is a prevalent burdensome condition affecting millions of Americans. Patch testing, the criterion-standard allergic contact dermatitis diagnostic tool, is underused by US dermatologists. Incorporating patch testing into modern dermatology practices is achievable with utilization of accurate resources and sustainable support. This review focuses on the basics of patch testing and provides practical pearls to assist novice providers in establishing a contact dermatitis specialty practice.
Get full access to this article
View all access options for this article.
References
1.
LimHW, CollinsSAB, ResneckJSJr., et al. The burden of skin disease in the United States. J Am Acad Dermatol, 2017; 76(5):958–972.
2.
ThyssenJP, LinnebergA, MenneT, et al.The epidemiology of contact allergy in the general population—prevalence and main findings. Contact Dermatitis, 2007; 57(5):287–299.
3.
OwenJL, VakhariaPP, SilverbergJI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol, 2018; 19(3):293–302.
4.
RamirezF, ChrenMM, BottoN. A review of the impact of patch testing on quality of life in allergic contact dermatitis. J Am Acad Dermatol, 2017; 76(5):1000–1004.
5.
American Dermatological Association. Journal of Cutaneous Diseases Including Syphilis. Chicago: American Dermatological Association;. 1903.
6.
BechetPE. The early history of American dermatology. Arch Derm Syphilol, 1942; 45(3):482–505.
7.
ParishLC. The importance of the history of dermatology: an American viewpoint. Clin Dermatol, 2019; 37(1):60–70.
8.
NelsonJ, MowadC, SunH. Allergic contact dermatitis and patch-testing education in US dermatology residencies in 2010. Dermatitis, 2012; 23(2):56–60.
WarshawEM, NelsonD. Prevalence of patch testing and methodology of dermatologists in the US: results of a cross-sectional survey. Am J Contact Dermatitis, 2002; 13(2):53–58.
11.
FarrellAL, WarshawEM, ZhaoY, et al.Prevalence and methodology of patch testing by allergists in the United States: results of a cross-sectional survey. Am J Contact Dermat, 2002; 13(4):157–163.
12.
AdmaniS, JacobSE. Allergic contact dermatitis in children: review of the past decade. Curr Allergy Asthma Rep, 2014; 14(4):421.
13.
JacobSE, BurkCJ, ConnellyEA. Patch testing: another steroid-sparing agent to consider in children. Pediatr Dermatol, 2008; 25(1):81–87.
14.
SukantoH, NaterJ, BleuminkE. Influence of topically applied corticosteroids on patch test reactions. Contact Dermatitis, 1981; 7(4):180–185.
15.
ClarkRA, RietschelRL. 0.1% triamcinolone acetonide ointment and patch test responses. Arch Dermatol, 1982; 118(3):163–165.
16.
HalprinKM, ComerfordM, PresserSE, et al.Ultraviolet light treatment delays contact sensitization to nitrogen mustard. Br J Dermatol, 1981; 105(1):71–76.
17.
RosmarinD, GottliebAB, AsarchA, et al.Patch-testing while on systemic immunosuppressants. Dermatitis, 2009; 20(5):265–270.
FonacierL, NoorI. Contact dermatitis and patch testing for the allergist. Ann Allergy Asthma Immunol, 2018; 120(6):592–598.
20.
FeuermanE, LevyA. A study of the effect of prednisone and an antihistamine on patch test reactions. Br J Dermatol, 1972; 86(1):68–71.
21.
MitchellJ. The angry back syndrome: eczema creates eczema. Contact Dermatitis, 1975; 1(4):193–194.
22.
de GrootAC. Patch Testing: Test Concentrations and Vehicles for 4350 Chemicals. Wapserveen, The Netherlands: deGroot; 2008.
23.
WinterR. A Consumer's Dictionary of Household, Yard and Office Chemicals: Complete Information About Harmful and Desirable Chemicals Found in Everyday Home Products, Yard Poisons, and Office Polluters. iUniverse; 2007.
24.
DeKovenJG, WarshawEM, ZugKA, et al.North American Contact Dermatitis Group patch test results: 2015–2016. Dermatitis, 2018; 29(6):297–309.
25.
SchalockPC, DunnickCA, NedorostS, et al.American Contact Dermatitis Society Core allergen series: 2017 update. Dermatitis, 2017; 28(2):141–143.
26.
Preliminary studies of the TRUE Test patch test system in the United States. TRUE Test study group. J Am Acad Dermatol, 1989; 21(4 pt 2):841–843.
27.
JacobSE, HerroEM, SullivanK, et al.Safety and efficacy evaluation of TRUE TEST panels 1.1, 2.1, and 3.1 in children and adolescents. Dermatitis, 2011; 22(4):204–210.
28.
MowadCM. Allergens of new and emerging significance. Dermatol Nurs, 2006; 18(6):545.
29.
DuarteI, LazzariniR, BuenseR. Interference of the position of substances in an epicutaneous patch test battery with the occurrence of false-positive results. Am J Contact Dermat, 2002; 13(3):125–132.
JouPC, SiegelPD, WarshawEM. Vapor pressure and predicted stability of American Contact Dermatitis Society core allergens. Dermatitis, 2016; 27(4):193–201.
32.
Frick-EngfeldtM, GruvbergerB, IsakssonM, et al.Comparison of three different techniques for application of water solutions to Finn Chambers®. Contact Dermatitis, 2010; 63(5):284–288.
33.
JohansenJD, Aalto-KorteK, AgnerT, et al.European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis, 2015; 73(4):195–221.
34.
HannukselaM. Sensitivity of various skin sites in the repeated open application test. Dermatitis, 1991; 2(2):102–104.
35.
SmithSM, ZirwasMJ. Nonallergic reactions to medical tapes. Dermatitis, 2015; 26(1):38–43.
36.
MowadCM, AndersonB, ScheinmanP, et al.Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol, 2016; 74(6):1029–1040.
37.
HigginsE, CollinsP. The relevance of 7-day patch test reading. Dermatitis, 2013; 24(5):237–240.
38.
WilkinsonDS, FregertS, MagnussonB, et al.Terminology of contact dermatitis. Acta Derm Venereol, 1970; 50(4):287–292.
39.
de Waard-van der SpekFB, DarsowU, MortzCG, et al.EAACI position paper for practical patch testing in allergic contact dermatitis in children. Pediatr Allergy Immunol, 2015; 26(7):598–606.
40.
LachapelleJM. A proposed relevance scoring system for positive allergic patch test reactions: practical implications and limitations. Contact Dermatitis, 1997; 36(1):39–43.
41.
HeisterbergMV, MennéT, JohansenJD. Contact allergy to the 26 specific fragrance ingredients to be declared on cosmetic products in accordance with the EU cosmetics directive. Contact Dermatitis, 2011; 65(5):266–275.
42.
FranswayAF, ZugKA, BelsitoDV, et al.North American Contact Dermatitis Group patch test results for 2007–2008. Dermatitis, 2013; 24(1):10–21.
43.
HannukselaM, SaloH. The repeated open application test (ROAT). Contact Dermatitis, 1986; 14(4):221–227.
44.
JohansenJD, BruzeM, AndersenKE, et al.The repeated open application test: suggestions for a scale of evaluation. Contact Dermatitis, 1998; 39(2):95–96.
45.
HaynesAB, WeiserTG, BerryWR, et al.A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med, 2009; 360(5):491–499.
46.
SelvickA, StaussK, StrobushK, et al.Standardizing the delivery of 20 μL of hapten during patch testing. Dermatitis, 2016; 27(5):272–275.
47.
WestonWL, WestonJA, KinoshitaJ, et al.Prevalence of positive epicutaneous tests among infants, children, and adolescents. Pediatrics, 1986; 78(6):1070–1074.
48.
BorokJ, MatizC, GoldenbergA, et al.Contact dermatitis in atopic dermatitis children-past, present, and future. Clin Rev Allergy Immunol, 2019; 56(1):86–98.
49.
YuJ, AtwaterAR, BrodB, et al.Pediatric baseline patch test series: pediatric contact dermatitis workgroup. Dermatitis, 2018; 29(4):206–212.
50.
WormM, AbererW, AgathosM, et al.Patch testing in children—recommendations of the German Contact Dermatitis Research Group (DKG). J German Soc Dermatol, 2007; 5(2):107–109.
51.
MatizC, JacobSE. Systemic contact dermatitis in children: how an avoidance diet can make a difference. Pediatr Dermatol, 2011; 28(4):368–374.
52.
HillAM, BelsitoDV. Systemic contact dermatitis of the eyelids caused by formaldehyde derived from aspartame?. Contact Dermatitis, 2003; 49(5):258–259.
53.
JacobSE, StechschulteS. Formaldehyde, aspartame, and migraines: a possible connection. Dermatitis, 2008; 19(3):E10–E11.
54.
WinnickiM, ShearNH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol, 2011; 12(3):171–180.
55.
HausermannP, HarrT, BircherAJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?. Contact Dermatitis, 2004; 51(5–6):297–310.
56.
MislankarM, ZirwasMJ. Low-nickel diet scoring system for systemic nickel allergy. Dermatitis, 2013; 24(4):190–195.
57.
GoldenbergA, JacobSE. Update on systemic nickel allergy syndrome and diet. Eur Ann Allergy Clin Immunol, 2015; 47(1):25–26.
FabbroSK, ZirwasMJ. Systemic contact dermatitis to foods: nickel, BOP, and more. Curr Allergy Asthma Rep, 2014; 14(10):463.
60.
de GrootA, FlyvholmMA. Formaldehyde and formaldehyde-releasers. In: JohnSM, JohansenJD, RustemeyerT, et al, eds. Kanerva's Occupational Dermatology. Cham: Springer International Publishing; 2018:1–32.
61.
SheehanMP. Therapeutics in allergic contact dermatitis, when avoidance fails. Curr Treat Options Allergy, 2014; 1(4):337–347.
62.
MachlerBC, SungCT, DarwinE, et al.Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol, 2019; 80(1):280–281.e281.
63.
JacobSE, SungCT, MachlerBC. Dupilumab for systemic allergy syndrome with dermatitis. Dermatitis, 2019; 30(2):164–167.
64.
RaffiJ, SureshR, BottoN, et al.The impact of dupilumab on patch testing and the prevalence of co-morbid ACD in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol, 2020; 82(1):132–138.
65.
SoJK, HamstraA, CalameA, et al.Another great imitator: allergic contact dermatitis differential diagnosis, clues to diagnosis, histopathology, and treatment. Curr Treat Options Allergy, 2015; 2(4):333–348.
